276 related articles for article (PubMed ID: 31883921)
1. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.
Suzuki D; Flahou C; Yoshikawa N; Stirblyte I; Hayashi Y; Sawaguchi A; Akasaka M; Nakamura S; Higashi N; Xu H; Matsumoto T; Fujio K; Manz MG; Hotta A; Takizawa H; Eto K; Sugimoto N
Stem Cell Reports; 2020 Jan; 14(1):49-59. PubMed ID: 31883921
[TBL] [Abstract][Full Text] [Related]
2. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
Flahou C; Morishima T; Takizawa H; Sugimoto N
Front Immunol; 2021; 12():662360. PubMed ID: 33897711
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.
Norbnop P; Ingrungruanglert P; Israsena N; Suphapeetiporn K; Shotelersuk V
Sci Rep; 2020 May; 10(1):8472. PubMed ID: 32439978
[TBL] [Abstract][Full Text] [Related]
4. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
5. Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and/or class II MHC molecules.
Pócsik E; Mihalik R; Réti M; Gyódi E; Pálóczi K; Mayer K; Kassai M; Herold M; Huber C; Petrányi GG
Immunobiology; 1990 Dec; 182(1):22-31. PubMed ID: 1983002
[TBL] [Abstract][Full Text] [Related]
6. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
Flahou C; Morishima T; Higashi N; Hayashi Y; Xu H; Wang B; Zhang C; Ninomiya A; Qiu WY; Yuzuriha A; Suzuki D; Nakamura S; Manz M; Kaneko S; Hotta A; Takizawa H; Eto K; Sugimoto N
Biochem Biophys Res Commun; 2023 Jun; 662():76-83. PubMed ID: 37099813
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cell Inhibition by HLA-E Molecules on Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelial Cells.
Sugita S; Makabe K; Iwasaki Y; Fujii S; Takahashi M
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1719-1731. PubMed ID: 29610856
[TBL] [Abstract][Full Text] [Related]
9. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
10. A ligand for the murine NK activation receptor Ly-49D: activation of tolerized NK cells from beta 2-microglobulin-deficient mice.
Furukawa H; Iizuka K; Poursine-Laurent J; Shastri N; Yokoyama WM
J Immunol; 2002 Jul; 169(1):126-36. PubMed ID: 12077237
[TBL] [Abstract][Full Text] [Related]
11. Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.
Goldenson BH; Zhu H; Wang YM; Heragu N; Bernareggi D; Ruiz-Cisneros A; Bahena A; Ask EH; Hoel HJ; Malmberg KJ; Kaufman DS
Front Immunol; 2020; 11():561553. PubMed ID: 33178188
[TBL] [Abstract][Full Text] [Related]
12. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
[TBL] [Abstract][Full Text] [Related]
13. Scalable generation of universal platelets from human induced pluripotent stem cells.
Feng Q; Shabrani N; Thon JN; Huo H; Thiel A; Machlus KR; Kim K; Brooks J; Li F; Luo C; Kimbrel EA; Wang J; Kim KS; Italiano J; Cho J; Lu SJ; Lanza R
Stem Cell Reports; 2014 Nov; 3(5):817-31. PubMed ID: 25418726
[TBL] [Abstract][Full Text] [Related]
14. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity.
Weiss EH; Lilienfeld BG; Müller S; Müller E; Herbach N; Kessler B; Wanke R; Schwinzer R; Seebach JD; Wolf E; Brem G
Transplantation; 2009 Jan; 87(1):35-43. PubMed ID: 19136889
[TBL] [Abstract][Full Text] [Related]
15. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
16. CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells.
Maeda M; Shadeo A; MacFadyen AM; Takei F
J Immunol; 2004 May; 172(10):6115-22. PubMed ID: 15128797
[TBL] [Abstract][Full Text] [Related]
17. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
18. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells.
Wang Z; Arienti F; Parmiani G; Ferrone S
Eur J Immunol; 1998 Sep; 28(9):2817-26. PubMed ID: 9754569
[TBL] [Abstract][Full Text] [Related]
19. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.
Baba T; Hanagiri T; Ichiki Y; Kuroda K; Shigematsu Y; Mizukami M; Sugaya M; Takenoyama M; Sugio K; Yasumoto K
Cancer Sci; 2007 Nov; 98(11):1795-802. PubMed ID: 17725806
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C; Blaszczyk R
J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
